SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    P. Emery, G. R. Burmester, V. P. Bykerk, B. G. Combe, D. E. Furst, E. Barre, C. S. Karyekar, D. A. Wong, T. W. J. Huizinga, Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period, Annals of the Rheumatic Diseases, 2015, 74, 1, 19

    CrossRef

  2. 2
    F. Ponchel, V. Goeb, R. Parmar, Y. El-Sherbiny, M. Boissinot, J. El Jawhari, A. Burska, E. M. Vital, S. Harrison, P. G. Conaghan, E. Hensor, P. Emery, An immunological biomarker to predict MTX response in early RA, Annals of the Rheumatic Diseases, 2014, 73, 11, 2047

    CrossRef

  3. 3
    M. B. Arnold, V. P. Bykerk, G. Boire, B. P. Haraoui, C. Hitchon, C. Thorne, E. C. Keystone, J. E. Pope, Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort, Rheumatology, 2014, 53, 6, 1075

    CrossRef

  4. 4
    María Victoria Martire, Lucila Marino Claverie, Vanesa Duarte, Anastasia Secco, Marta Mammani, Factores asociados a remisión sostenida en pacientes con artritis reumatoide, Reumatología Clínica, 2014,

    CrossRef

  5. 5
    Fabiola Atzeni, Sara Bongiovanni, Antonio Marchesoni, Matteo Filippini, Roberto Caporali, Roberto Gorla, Lorenzo Cavagna, Ennio-Giulio Favalli, Francesco Saccardo, Piercarlo Sarzi-Puttini, Prédicteurs de la réponse aux traitements anti-TNF chez les patients ayant une polyarthrite rhumatoïde avec des scores DAS28 modérés ou élevés, Revue du Rhumatisme, 2014, 81, 1, 54

    CrossRef

  6. 6
    Claire I. Daïen, Jacques Morel, Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine, Mediators of Inflammation, 2014, 2014, 1

    CrossRef

  7. 7
    Fabiola Atzeni, Sara Bongiovanni, Antonio Marchesoni, Matteo Filippini, Roberto Caporali, Roberto Gorla, Lorenzo Cavagna, Ennio Giulio Favalli, Francesco Saccardo, Piercarlo Sarzi-Puttini, Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores, Joint Bone Spine, 2014, 81, 1, 37

    CrossRef

  8. 8
    Marcello Govoni, Alessandra Bortoluzzi, Andrea Lo Monaco, Silvano Adami, Olga Addimanda, Cristian Caimmi, Salvatore De Vita, Clodoveo Ferri, Andreina Manfredi, Giovanni Orsolini, Niccolò Possemato, Luca Quartuccio, Carlo Salvarani, Alen Zabotti, Maurizio Rossini, Therapeutic Options After Treatment Failure in Rheumatoid Arthritis or Spondyloarthritides, Advances in Therapy, 2014, 31, 8, 780

    CrossRef

  9. 9
    Gábor Futó, Attila Somogyi, Zoltán Szekanecz, Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis, Clinical Rheumatology, 2014, 33, 5, 623

    CrossRef

  10. 10
    Cristina Pomirleanu, Codrina Ancuta, Smaranda Miu, Rodica Chirieac, A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers, Clinical Rheumatology, 2013, 32, 5, 665

    CrossRef

  11. 11
    V. K. Ranganath, P. Maranian, D. A. Elashoff, T. Woodworth, D. Khanna, T. Hahn, C. Sarkisian, J. M. Kremer, D. E. Furst, H. E. Paulus, Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis, Rheumatology, 2013, 52, 10, 1809

    CrossRef

  12. 12
    Stefan Kleinert, Hans-Peter Tony, Andreas Krause, Martin Feuchtenberger, Siegfried Wassenberg, Constanze Richter, Ekkehard Röther, Wolfgang Spieler, Holger Gnann, Bianca M. Wittig, Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study, Rheumatology International, 2012, 32, 9, 2759

    CrossRef

  13. 13
    John M. Davis, Eric L. Matteson, My Treatment Approach to Rheumatoid Arthritis, Mayo Clinic Proceedings, 2012, 87, 7, 659

    CrossRef

  14. 14
    Damini Jawaheer, Susan Messing, George Reed, Veena K. Ranganath, Joel M. Kremer, James S. Louie, Dinesh Khanna, Jeffrey D. Greenberg, Daniel E. Furst, Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of north america cohort of rheumatoid arthritis patients, Arthritis Care & Research, 2012, 64, 12
  15. 15
    Y. M. R. de Punder, J. Fransen, W. Kievit, P. M. Houtman, H. Visser, M. A. F. J. van de Laar, P. L. C. M. van Riel, The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry, Rheumatology, 2012, 51, 9, 1610

    CrossRef

  16. 16
    Montserrat Robustillo Villarino, Jesús Rodríguez Moreno, ¿Son útiles los factores pronóstico en la artritis reumatoide?, Reumatología Clínica, 2011, 7, 5, 339

    CrossRef

  17. 17
    David T. Felson, Josef S. Smolen, George Wells, Bin Zhang, Lilian H. D. van Tuyl, Julia Funovits, Daniel Aletaha, Cornelia F. Allaart, Joan Bathon, Stefano Bombardieri, Peter Brooks, Andrew Brown, Marco Matucci-Cerinic, Hyon Choi, Bernard Combe, Maarten de Wit, Maxime Dougados, Paul Emery, Daniel Furst, Juan Gomez-Reino, Gillian Hawker, Edward Keystone, Dinesh Khanna, John Kirwan, Tore K. Kvien, Robert Landewé, Joachim Listing, Kaleb Michaud, Emilio Martin-Mola, Pamela Montie, Theodore Pincus, Pamela Richards, Jeffrey N. Siegel, Lee S. Simon, Tuulikki Sokka, Vibeke Strand, Peter Tugwell, Alan Tyndall, Desirée van der Heijde, Suzan Verstappen, Barbara White, Frederick Wolfe, Angela Zink, Maarten Boers, American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials, Arthritis & Rheumatism, 2011, 63, 3
  18. 18
    Montserrat Robustillo Villarino, Jesús Rodríguez Moreno, Are Prognostic Factors Useful in Rheumatoid Arthritis?, Reumatología Clínica (English Edition), 2011, 7, 5, 339

    CrossRef

  19. 19
    Denis Poddubnyy, Martin Rudwaleit, Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, Expert Opinion on Drug Safety, 2011, 10, 4, 655

    CrossRef

  20. 20
    Daniel E. Furst, Aileen L. Pangan, Leslie R. Harrold, Hong Chang, George Reed, Joel M. Kremer, Jeffrey D. Greenberg, Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry, Arthritis Care & Research, 2011, 63, 6
  21. 21
    Per Qvist, Anne-Christine Bay-Jensen, Claus Christiansen, Bodil Cecilie Sondergaard, Morten A. Karsdal, Molecular serum and urine marker repertoire supporting clinical research on joint diseases, Best Practice & Research Clinical Rheumatology, 2011, 25, 6, 859

    CrossRef

  22. 22
    C. Deighton, K. Hyrich, T. Ding, J. Ledingham, M. Lunt, R. Luqmani, P. Kiely, M. Bukhari, R. Abernethy, A. Ostor, A. Bosworth, K. Gadsby, F. McKenna, D. Finney, J. Dixey, BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy, Rheumatology, 2010,

    CrossRef

  23. 23
    Xavier Le Loët, Marie Kozyreff Meurice, Thierry Lequerré, Olivier Vittecoq, Polyarthrite rhumatoïde : définitions de la réponse, des différents niveaux d’activité et de la rémission, Revue du Rhumatisme Monographies, 2010, 77, 1, 22

    CrossRef

  24. 24
    Wanruchada Katchamart, Sindhu Johnson, Hsing-Ju Lucy Lin, Veerapong Phumethum, Carine Salliot, Claire Bombardier, Predictors for remission in rheumatoid arthritis patients: A systematic review, Arthritis Care & Research, 2010, 62, 8
  25. 25
    Veena K Ranganath, Sogol Amjadi, Edmond Melikterminas, Daniel E Furst, The older rheumatoid arthritis patients: who are they and how should they be treated?, Aging Health, 2010, 6, 5, 533

    CrossRef

  26. 26
    Nobuyuki Miyasaka, Adalimumab for the treatment of rheumatoid arthritis, Expert Review of Clinical Immunology, 2009, 5, 1, 19

    CrossRef

  27. 27
    K. L. Hyrich, C. Deighton, K. D. Watson, D. P. M. Symmons, M. Lunt, Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity, Rheumatology, 2009, 48, 10, 1323

    CrossRef

  28. 28
    Diane van der Woude, Adam Young, Keeranur Jayakumar, Bart J. Mertens, René E. M. Toes, Désirée van der Heijde, Tom W. J. Huizinga, Annette H. M. van der Helm-van Mil, Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug–free remission in rheumatoid arthritis: Results from two large early arthritis cohorts, Arthritis & Rheumatism, 2009, 60, 8
  29. 29
    Josef S Smolen, Daniel Aletaha, Activity assessments in rheumatoid arthritis, Current Opinion in Rheumatology, 2008, 20, 3, 306

    CrossRef

  30. 30
    In Briefs, Nature Clinical Practice Rheumatology, 2008, 4, 5, 232

    CrossRef

  31. 31
    C. Deighton, K. Hyrich, Why do the French get much greater access to anti-TNF than the British? Vive la difference? Pas necessairement, Rheumatology, 2008, 47, 11, 1600

    CrossRef